132 related articles for article (PubMed ID: 38712286)
1. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
Floros KV; Fairchild CK; Li J; Zhang K; Roberts JL; Kurupi R; Hu B; Kraskauskiene V; Hosseini N; Shen S; Inge MM; Smith-Fry K; Li L; Sotiriou A; Dalton KM; Jose A; Abdelfadiel EI; Xing Y; Hill RD; Slaughter JM; Shende M; Lorenz MR; Hinojosa MR; Belvin BR; Lai Z; Boikos SA; Stamatouli AM; Lewis JP; Manjili MH; Valerie K; Li R; Banito A; Poklepovic A; Koblinski JE; Siggers T; Dozmorov MG; Jones KB; Radhakrishnan SK; Faber AC
bioRxiv; 2024 Apr; ():. PubMed ID: 38712286
[TBL] [Abstract][Full Text] [Related]
2. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
3. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
[TBL] [Abstract][Full Text] [Related]
4. Differential Modulation of Polycomb-Associated Histone Marks by cBAF, pBAF, and gBAF Complexes.
Bergwell M; Park J; Kirkland JG
bioRxiv; 2024 Jan; ():. PubMed ID: 37790495
[TBL] [Abstract][Full Text] [Related]
5. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
6. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
[TBL] [Abstract][Full Text] [Related]
7. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
9. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
10. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
Kadoch C; Crabtree GR
Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691
[TBL] [Abstract][Full Text] [Related]
11. A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.
Baranov E; McBride MJ; Bellizzi AM; Ligon AH; Fletcher CDM; Kadoch C; Hornick JL
Am J Surg Pathol; 2020 Jul; 44(7):922-933. PubMed ID: 32141887
[TBL] [Abstract][Full Text] [Related]
12. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
[TBL] [Abstract][Full Text] [Related]
13. Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.
Ishii M; Suehara Y; Sano K; Kohsaka S; Hayashi T; Kazuno S; Akaike K; Mukaihara K; Kim Y; Okubo T; Takamochi K; Takahashi F; Kaneko K; Saito T
Oncotarget; 2018 Dec; 9(101):37509-37519. PubMed ID: 30680066
[TBL] [Abstract][Full Text] [Related]
14. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
[TBL] [Abstract][Full Text] [Related]
15. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
16. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
17. SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.
St Pierre R; Collings CK; Samé Guerra DD; Widmer CJ; Bolonduro O; Mashtalir N; Sankar A; Liang Y; Bi WL; Gerkes EH; Ramesh V; Qi J; Smith MJ; Meredith DM; Kadoch C
Nat Genet; 2022 Jun; 54(6):861-873. PubMed ID: 35681054
[TBL] [Abstract][Full Text] [Related]
18. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
[TBL] [Abstract][Full Text] [Related]
19. [Expression of SS18-SSX fusion-specific antibody and SSX C-terminal antibody in synovial sarcoma and its diagnostic value].
Wang X; Cheng K; Wu N; Li R; Chen H; Ma HH; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):740-744. PubMed ID: 34405607
[No Abstract] [Full Text] [Related]
20. Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma.
Miura K; Shimizu K; Eguchi T; Koike S; Matsuoka S; Takeda T; Hamanaka K; Uehara T
Diagn Pathol; 2021 Jun; 16(1):54. PubMed ID: 34127031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
